The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling

Anti-Cancer Activity of Nitrones and Observations on Mechanism of Action

(2012) Robert A. Floyd et al.   Anti-Cancer Agents in Medicinal Chemistry

Hepatocellular Carcinoma

(2011) Nuh N. Rahbari et al.   ANNALS OF SURGERY

Effects of PBN and OKN007 in rodent glioma models assessed by 1H MR spectroscopy

(2011) Ting He et al.   FREE RADICAL BIOLOGY AND MEDICINE

SULFs in human neoplasia: implication as progression and prognosis factors

(2011) Caroline Bret et al.   Journal of Translational Medicine

Novel molecular therapies in hepatocellular carcinoma

(2011) Sandrine Faivre et al.   LIVER INTERNATIONAL

hSulf-1 Gene Exhibits Anticancer Efficacy through Negatively Regulating VEGFR-2 Signaling in Human Cancers

(2011) Weidan Ji et al.   PLoS One

Translational Stroke Research of the Combination of Thrombolysis and Antioxidant Therapy

(2011) Sergio Amaro et al.   STROKE

Glucosamine-6-sulfamate Analogues of Heparan Sulfate as Inhibitors of Endosulfatases

(2010) Mathias Schelwies et al.   CHEMBIOCHEM

Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate

(2010) Steven D Rosen et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: Associated signaling pathways, tumor phenotypes, and survival

(2010) Ju Dong Yang et al.   GENES CHROMOSOMES & CANCER

The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation

(2010) Jin-Ping Lai et al.   HEPATOLOGY

Multiparametric assessment of the anti-glioma properties of OKN007 by magnetic resonance imaging

(2010) Philippe Garteiser et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors

(2010) Jin-Ping Lai et al.   LIVER INTERNATIONAL

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

(2010) S Whittaker et al.   ONCOGENE

Pharmacokinetics of 8-hour intravenous infusion of NXY-059: A phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers

(2009) Yi-Fang Cheng et al.   CLINICAL THERAPEUTICS

Primary liver tumors: origin and target therapy

(2009) Michail Papoulas et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Molecular targeted therapy for hepatocellular carcinoma

(2009) Melanie Thomas   JOURNAL OF GASTROENTEROLOGY

Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis

(2009) H Lemjabbar-Alaoui et al.   ONCOGENE

Factors Associated With Intracerebral Hemorrhage After Thrombolytic Therapy for Ischemic Stroke

(2009) Brett Cucchiara et al.   STROKE

Systemic therapy of hepatocellular carcinoma: Are we making progress?

(2008) Patricia Roxburgh et al.   ADVANCES IN THERAPY

Nitrones as therapeutics

(2008) Robert A. Floyd et al.   FREE RADICAL BIOLOGY AND MEDICINE

Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma

(2008) Jin-Ping Lai et al.   HEPATOLOGY

NXY-059 for the Treatment of Acute Stroke

(2008) Hans-Christoph Diener et al.   STROKE

Treatment options for hepatocellular carcinoma

(2008) Dalbir S Sandhu et al.   Expert Review of Gastroenterology & Hepatology